Pharmaceutical formulation
A formulation for oral administration comprises an expectorant, an analgesic, and at least one additional active ingredient having a modified release providing a therapeutic effect for each of the active ingredients for up to 12 hours.
1. A pharmaceutical composition comprising:
(a) about 600 mg of guaifenesin;
(b) about 30 mg of dextromethorphan or a pharmaceutically acceptable salt thereof;
(c) about 110 mg of naproxen or a pharmaceutically acceptable salt thereof;
(d) about 28 mg of hypromellose;
(e) about 61.29 mg of microcrystalline cellulose;
(f) about 14 mg of hydroxyethyl cellulose;
(g) about 23 mg of croscarmellose sodium;
(h) about 10 mg of sodium lauryl sulfate;
(i) about 60 mg of sodium bicarbonate;
(j) about 51.45 mg of polyethylene glycol 4000; and
(k) about 5.8 to 9 mg of magnesium stearate;
wherein the pharmaceutical composition provides a therapeutic effect in respect of each of guaifenesin, naproxen, and dextromethorphan for 12 hours;
wherein substantially all of naproxen dissolves within 30 minutes in a pH 6.8 phosphate buffer; and
wherein the pharmaceutical composition is a bilayer tablet comprising an immediate release layer containing substantially all of the naproxen and at least about 100 mg of the guaifenesin and at least about 8 mg of the dextromethorphan, wherein the immediate release layer contains none of the hypromellose, and wherein the immediate release layer contains none of the hydroxyethyl cellulose.
2. The pharmaceutical composition according to claim 1 , wherein the immediate release layer contains substantially all of the sodium lauryl sulfate and substantially all of the sodium bicarbonate.
3. A pharmaceutical composition comprising:
(a) about 600 mg of guaifenesin;
(b) about 30 mg of dextromethorphan or a pharmaceutically acceptable salt thereof;
(c) about 110 mg of naproxen or a pharmaceutically acceptable salt thereof;
(d) about 18 to 28 mg of hypromellose;
(e) about 61.29 mg of microcrystalline cellulose;
(f) about 8 to 14 mg of hydroxyethyl cellulose;
(g) about 23 mg of croscarmellose sodium;
(h) about 10 mg of sodium lauryl sulfate;
(i) about 60 mg of sodium bicarbonate;
(j) about 51.45 mg of polyethylene glycol 4000; and
(k) about 5.8 to 9 mg of magnesium stearate;
wherein the pharmaceutical composition provides a therapeutic effect in respect of each of guaifenesin, naproxen, and dextromethorphan for 12 hours;
wherein substantially all of naproxen dissolves within 30 minutes in a pH 6.8 phosphate buffer; and
wherein the pharmaceutical composition is a bilayer tablet comprising an immediate release layer containing substantially all of the naproxen and at least about 100 mg of the guaifenesin and at least about 8 mg of the dextromethorphan, wherein the immediate release layer contains none of the hypromellose, and wherein the immediate release layer contains none of the hydroxyethyl cellulose.
4. The pharmaceutical composition according to claim 3 , wherein the immediate release layer contains substantially all of the sodium lauryl sulfate and substantially all of the sodium bicarbonate.
5. A pharmaceutical composition comprising:
(a) about 600 mg of guaifenesin;
(b) about 30 mg of dextromethorphan or a pharmaceutically acceptable salt thereof;
(c) about 110 mg of naproxen or a pharmaceutically acceptable salt thereof;
(d) about 18 to 28 mg of hypromellose;
(e) about 61.29 mg of microcrystalline cellulose;
(f) about 8 to 14 mg of hydroxyethyl cellulose;
(g) about 23 mg of croscarmellose sodium;
(h) about 10 mg of sodium lauryl sulfate;
(i) about 60 mg of sodium bicarbonate;
(j) about 51.45 mg of polyethylene glycol 4000; and
(k) about 5.8 to 9 mg of magnesium stearate;
wherein the pharmaceutical composition provides a therapeutic effect in respect of each of guaifenesin, naproxen, and dextromethorphan for 12 hours;
wherein substantially all of naproxen dissolves within 30 minutes in a pH 6.8 phosphate buffer;
wherein the dissolution profile of naproxen is substantially the same as a dissolution profile of naproxen in an immediate release pharmaceutical composition containing 220 mg of naproxen which does not contain guaifenesin and dextromethorphan; and
wherein the pharmaceutical composition is a bilayer tablet comprising an immediate release layer containing substantially all of the naproxen and at least about 100 mg of the guaifenesin and at least about 8 mg of the dextromethorphan, wherein the immediate release layer contains none of the hypromellose, and wherein the immediate release layer contains none of the hydroxyethyl cellulose.
6. The pharmaceutical composition according to claim 5 , wherein the immediate release layer contains substantially all of the sodium lauryl sulfate and substantially all of the sodium bicarbonate.